TRADE DEADLINE: Head Coach rejected $98.9 million offer from the …see more

Briane Harris’s absence from Canada’s national women’s curling championship has officially been explained.

The 31-year-old from Winnipeg was declared ineligible to compete in the Scotties Tournament of Hearts in Calgary hours before her team skipped by Kerri Einarson played its opening game Feb. 16. The Einarson rink, Harris’s lawyer, Curling Canada, and the World Curling all issued separate statements on Tuesday confirming that she had been banned due to a doping violation.

“Curling Canada was deeply disappointed to receive the news of Briane Harris’s adverse analytical finding on the opening day of the Tournament of Hearts,” reads a statement from Curling Canada. “Our organization is committed to the values of clean and safe sport, as outlined by both the World Anti-Doping Agency and the Canadian Centre for Ethics in Sport.

We respect the integrity of the testing process and accept the results of the test, as well as Briane’s right to appeal the findings.”

 

Harris tested positive for trace amounts of Ligandrol in an out-of-competition doping control test conducted on Jan. 24. She got her positive results on the evening of Feb. 15 and informed Curling Canada of the violation the following morning as she headed to practice.

 

She asked the Canadian Centre for Ethics in Sports, the body that conducts doping testing both in competition and outside of competition, to open her B sample and re-test, but again it was found to be positive.

 

Curling Canada CEO Nolan Thiessen said in a video conference on Tuesday that at this point in the process the sport’s national governing body is a bystander and will abide by any legal ruling on the issue.

“She has her right to due process and the right to appeal,” said Thiessen. “We totally support all of our athletes in any of these situations.”

 

Ligandrol is on the World Anti-Doping Agency’s list of prohibited substances. It is used to increase energy and muscle growth. According to the United States Doping Agency, there is no medical use for LGD-4033, the developmental code name for Ligandrol.

“As best as can be determined at this time, Ms. Harris was unknowingly exposed to the banned substance through bodily contact,” said Harris’s lawyer Amanda Fowler in a statement. “In the circumstances, Ms. Harris is therefore keen to clear her name and will seek to expedite any process of mechanism to facilitate such vindication.”

 

Harris could face a two-year suspension under CCES regulations, although there is the flexibility to decrease or increase a sanction depending on the facts of a case and the results of tests.

Be the first to comment

Leave a Reply

Your email address will not be published.


*